Michael Sharpe is a British psychiatrist and academic, specialising in the psychiatric aspects of medical illness. He is an Emeritus Professor of Psychological Medicine at the University of Oxford and a Fellow of Saint Cross College, Oxford. From 1997 to 2011, he was Professor of Psychological Medicine at the University of Edinburgh. [1] [2] Sharpe was the elected President of the European Association of Psychosomatic Medicine for 2022-2023. [3]
While a Professor at Oxford, Sharpe ran a research programme to develop and evaluate psychiatric treatments for medically ill patients. [4]
Sharpe has worked on the CFS/ME for years, and is perhaps best known as a co-author on the controversial PACE trial which found exercise and cognitive behavioural therapy to be “moderately effective” treatments for Myalgic Encephalomyelitis. [5] He, like many other CFS researchers, such as Simon Wessely, has since then withdrawn from CFS/ME research, saying the climate had become “too toxic” because of online abuse from some patients who reject any hint of a psychiatric element to the illness. [6]
In 2021 he controversially gave a presentation on secondary covid 19 impacts [7] to Swiss Re in which he suggested that Long COVID was partly caused by psychological and social factors such as reportage by the Guardian columnist George Monbiot. [8]
Sharpe's recent work is on depression in people with cancer and the mental health of elderly inpatients. [9]
In 2009, he was named Psychiatric Academic of the Year by the Royal College of Psychiatrists. [10] In 2014, he was named Psychiatrist of the Year by the Royal College of Psychiatrists. [11]